FOXO4-DRI

FOXO4-DRI is a synthetic all-D-amino acid retro-inverso peptide that acts as a senolytic agent — a compound that selectively triggers apoptosis in senescent cells while sparing non-senescent tissue. It was developed by Baar et al. and published in Cell in 2017, representing one of the most influential papers in the cellular senescence field.

FOXO4-DRI stands for: **FOXO4** (the target transcription factor) + **D** (D-amino acid configuration) + **RI** (retro-inverso — reversed sequence). The D-retro-inverso strategy produces a mirror-image peptide that mimics the three-dimensional shape of the parent L-amino acid peptide but is highly resistant to proteolytic degradation.

As a research compound, FOXO4-DRI has no approved indication, no human clinical trial data, and no established human dosing. It is sold by research peptide vendors as a lyophilized compound for preclinical investigation.

Senescent cells — cells that have permanently exited the cell cycle in response to DNA damage, oxidative stress, or replicative exhaustion — accumulate with aging and contribute to tissue dysfunction through the SASP (senescence-associated secretory phenotype), a pro-inflammatory secretome.

In senescent cells, FOXO4 forms a complex with p53 in nuclear PML bodies, sequestering p53 and preventing it from triggering apoptosis. This FOXO4-p53 interaction is essential for the survival of senescent cells against their own pro-apoptotic signals.

FOXO4-DRI disrupts the FOXO4-p53 protein-protein interaction by competitively binding FOXO4 at the p53 interaction interface. This releases p53 from nuclear sequestration, allowing it to translocate to mitochondria and activate the intrinsic apoptotic cascade (caspase-3/7 dependent) — specifically in senescent cells where the FOXO4-p53 interaction is active. Non-senescent cells have minimal FOXO4-p53 co-localization, explaining the selectivity.